To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Is plasma amyloid-beta a … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?

Review article
Authors Henrik Zetterberg
Published in Recent patents on CNS drug discovery
Volume 3
Issue 2
Pages 109-11
ISSN 1574-8898
Publication year 2008
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 109-11
Language en
Links www.ncbi.nlm.nih.gov/entrez/query.f...
Keywords Alzheimer Disease, blood, cerebrospinal fluid, economics, Amyloid beta-Protein, blood, cerebrospinal fluid, Biological Markers, Cognition Disorders, blood, cerebrospinal fluid, etiology, Humans, Peptide Fragments, blood, cerebrospinal fluid
Subject categories Medical and Health Sciences

Abstract

Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-beta (Abeta(42)) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimer's disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the clinical routine and in clinical trials, there is a strong interest in the possible association of Abeta levels in plasma with AD. This review provides an update on the current status of research on plasma Abeta as a biomarker for AD in the context of recent patents in the field.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?